William Johnson, MD
Family Medicine · Farmington, MONPI 1255371944
Payments from drug & device makers
Across 212 payments — averaging $13.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$389
- Pfizer$338
- AstraZeneca$259
- Boehringer Ingelheim$222
- Lilly USA, LLC$180
- Johnson & Johnson$174
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,73898%
- Education$682%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 19 | $389 |
| Pfizer | 34 | $338 |
| AstraZeneca | 9 | $259 |
| Boehringer Ingelheim | 16 | $222 |
| Lilly USA, LLC | 15 | $180 |
| Johnson & Johnson | 10 | $174 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $148 |
| Amgen | 13 | $147 |
| Sanofi-aventis U.S. LLC | 12 | $147 |
| GSK | 17 | $144 |
| Novo Nordisk | 10 | $128 |
| Daiichi Sankyo Inc. | 5 | $95 |
| Sunovion Pharmaceuticals Inc. | 7 | $75 |
| Regeneron Healthcare Solutions, Inc. | 4 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $44 |
| Amarin Pharma, Inc. | 3 | $39 |
| Novartis | 3 | $37 |
| Indivior Inc. | 2 | $33 |
| Lundbeck LLC | 1 | $23 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Merck | 1 | $13 |
| Gilead | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
| Mylan Specialty L.p. | 1 | $11 |
How this compares
$2,806 in reported general payments places this provider in the 80th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 467 | $365,013 |
| OzempicSemaglutide | 252 | $252,182 |
| EliquisApixaban | 505 | $230,782 |
| TrulicityDulaglutide | 184 | $224,826 |
| MounjaroTirzepatide | 97 | $131,086 |
| FarxigaDapagliflozin Propanediol | 144 | $87,107 |
| EntrestoSacubitril/Valsartan | 130 | $67,698 |
| ZenpepLipase/Protease/Amylase | 20 | $53,281 |
| JanuviaSitagliptin Phosphate | 74 | $52,308 |
| LinzessLinaclotide | 79 | $45,030 |
| ActemraTocilizumab | 17 | $43,493 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $43,088 |
| XareltoRivaroxaban | 49 | $33,922 |
| Xtampza ErOxycodone Myristate | 23 | $29,137 |
| Nurtec OdtRimegepant Sulfate | 25 | $28,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Spiriva Respimat, Stiolto Respimat | $222 | $438,861565 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $180 | $355,913281 claims |
| PfizerEliquis, Nurtec Odt | $338 | $259,270530 claims |
| Novo NordiskOzempic | $128 | $252,182252 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Anoro Ellipta | $144 | $89,876163 claims |
| AstraZenecaFarxiga | $259 | $87,107144 claims |
| NovartisEntresto | $37 | $67,698130 claims |
| MerckJanuvia | $13 | $52,30874 claims |
| AbbVieLinzess | $389 | $45,03079 claims |
| Johnson & JohnsonXarelto | $174 | $33,92249 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $44 | $11,20117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Farmington
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.